ESR1 Mutated Metastatic Breast Cancer Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 - DelveInsight

DelveInsight's "ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the ESR1 Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ESR1 Mutated Metastatic Breast Cancer Market Forecast
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the ESR1 Mutated Metastatic Breast Cancer Market Report:
• The ESR1 Mutated Metastatic Breast Cancer market size was valued approximately USD 1,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036).
• In May 2026, FDA approves vepdegestrant (Veppanu, the U.S. FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, identified using an FDA-authorized diagnostic test, following disease progression after at least one line of endocrine therapy. The approval established the first PROTAC estrogen receptor degrader for breast cancer.
• In February 2026, FDA accepts NDA for giredestrant: The U.S. FDA accepted Genentech/Roche's New Drug Application (NDA) for giredestrant in combination with everolimus for patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. The filing was supported by results from the Phase III evERA trial.
• In June 2025, Vepdegestrant (ARV-471), an experimental oral selective estrogen receptor degrader (SERD), has showan a statistically significant and clinically relevant improvement in progression-free survival (PFS) compared to fulvestrant (Faslodex) in patients with previously treated ESR1-mutant, estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer.
• In May 2025, Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) have shared comprehensive findings from the Phase 3 VERITAC-2 clinical trial (NCT05654623), which assessed vepdegestrant as a monotherapy against fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC). The study focused on patients whose disease had progressed following prior treatment with CDK4/6 inhibitors and endocrine therapy. These results were featured during the American Society of Clinical Oncology (ASCO®) press briefing and recognized in the Best of ASCO selections.
• In April 2025, AstraZeneca recently reported promising interim topline results from the SERENA-6 Phase III trial, a randomized, multicenter, double-blind study. The trial assessed the efficacy of camizestrant, an investigational next-generation oral selective estrogen receptor degrader (SERD), when used in combination with one of three CDK4/6 inhibitors-Pfizer's Ibrance, Eli Lilly's Verzenio, or Novartis' Kisqali-compared to the standard aromatase inhibitor plus CDK4/6 inhibitor regimen. This first-line treatment approach targeted patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer carrying a detectable estrogen receptor alpha (ESR1) mutation.
• In April 2025, Breast cancer research is advancing swiftly, with ongoing clinical trials and innovative therapies bringing renewed optimism for patients. Notable developments include recent results from the EMBER-3 trial (NCT04975308), the growing prominence of antibody-drug conjugates (ADCs), and the promising outlook for emerging treatment options.
• In March 2025, Results from the Phase III VERITAC-2 trial (NCT05654623) showed that vepdegestrant (ARV-471) as a monotherapy significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor 1-mutant (ESR1m) advanced or metastatic breast cancer. However, the treatment did not meet the threshold for statistical significance in the overall intent-to-treat (ITT) population.
• The total market size of ESR1-mutated Metastatic Breast Cancer in the 7MM is approximately USD 1,300 million in 2023 and is projected to increase during the forecast period (2026-2036).
• According to DelveInsight estimates, the US accounted for the maximum share of the total market in the 7MM, i.e., around 63%, followed by EU4 and the UK combined, capturing nearly 29% share in 2023.
• Among EU4 countries, Germany accounts for the maximum market size in 2023, i.e approximately USD 90 million.
• In the United States, aromatase inhibitor + CDK4/6 inhibitor is expected to garner the highest market share in the first-line setting, with a revenue of approximately USD 500 million, in 2023.
• Key therapies with Fast track designation (FTD) for ESR1 mutation includes Camizestrant, Lasofoxifene and OP-1250.
• The total number of prevalent cases of breast cancer in the US was nearly 1.14 million in 2025.
• The total number of diagnosed prevalent cases of HR positive breast cancer in the 7MM was nearly 1.26 million in 2025.
• The total cases of metastatic breast cancer in the United States was approximately 164,000 in 2025. Furthermore, these cases are expected to increase by 2036.
• In 2025, among EU4 and the UK, Germany had the highest cases of ESR1-mutated HR positive MBC with approximately 5,200 cases, followed by France (4,300 cases). Spain had the least cases.
• Key ESR1 Mutated Metastatic Breast Cancer Companies: AstraZeneca, Sermonix Pharmaceuticals, Sun Pharma Advanced Research Company, Radius Pharmaceuticals/ Menarini Group, Pfizer, G1 Therapeutics, Sanofi, Sun PharmaAdvanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine/ Eisai, Roche, and others
• Key ESR1 Mutated Metastatic Breast Cancer Therapies: Camizestrant (AZD9833), Lasofoxifene, SCO-120, Elacestrant (RAD1901), Ibrance (Palbociclib), Amcenestrant, Rintodestrant (G1T48), G1 Therapeutics, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant(RG6171, GDC9545), and others
• The ESR1 Mutated Metastatic Breast Cancer epidemiology based on Treatment Line-specific Cases analyzed that in 2021 out of the total diagnosed prevalent cases of ESR1 Mutated Metastatic Breast Cancer, in the United States, 72% were from the first-line
• The ESR1 Mutated Metastatic Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ESR1 Mutated Metastatic Breast Cancer pipeline products will significantly revolutionize the ESR1 Mutated Metastatic Breast Cancer market dynamics.

ESR1 Mutated Metastatic Breast Cancer Overview
ESR1 mutated metastatic breast cancer refers to a subtype of breast cancer where mutations occur in the estrogen receptor 1 (ESR1) gene. The ESR1 gene encodes the estrogen receptor alpha, a protein that plays a critical role in breast cancer growth and progression by responding to estrogen signals. Mutations in the ESR1 gene can lead to changes in the estrogen receptor protein, rendering it more active and resistant to hormonal therapies like tamoxifen or aromatase inhibitors.

Get a Free sample for the ESR1 Mutated Metastatic Breast Cancer Market Report:
https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

ESR1 Mutated Metastatic Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

ESR1 Mutated Metastatic Breast Cancer Epidemiology Segmentation:
The ESR1 Mutated Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalence of ESR1 Mutated Metastatic Breast Cancer
• Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer by severity
• Gender-specific Prevalence of ESR1 Mutated Metastatic Breast Cancer
• Diagnosed Cases of Episodic and Chronic ESR1 Mutated Metastatic Breast Cancer

Download the report to understand which factors are driving ESR1 Mutated Metastatic Breast Cancer epidemiology trends @ ESR1 Mutated Metastatic Breast Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

ESR1 Mutated Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1 Mutated Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers ESR1 Mutated Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the ESR1 Mutated Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

ESR1 Mutated Metastatic Breast Cancer Therapies and Key Companies
• ORSERDU (elacestrant): Stemline Therapeutics (a wholly owned subsidiary of the Menarini Group)
• Camizestrant (AZD9833): AstraZeneca
• Lasofoxifene: Sermonix Pharmaceuticals
• Elacestrant (RAD1901): Radius Pharmaceuticals/ Menarini Group
• Ibrance (Palbociclib): Pfizer
• Amcenestrant: Sanofi
• Rintodestrant (G1T48): G1 Therapeutics
• G1 Therapeutics: Sun PharmaAdvanced Research Company
• ZB716: Zenopharm
• ARV-471: Arvinas
• Lasofoxifene: SermonixPharmaceuticals
• H3B-6545: H3 Biomedicine/ Eisai
• Giredestrant(RG6171, GDC9545): Roche

Discover more about therapies set to grab major ESR1 Mutated Metastatic Breast Cancer market share @ ESR1 Mutated Metastatic Breast Cancer Treatment Market
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

ESR1 Mutated Metastatic Breast Cancer Market Drivers
• Increasing Detection of ESR1 Mutations: Wider adoption of next-generation sequencing (NGS) and liquid biopsy testing is improving identification of ESR1 mutations in metastatic breast cancer patients.
• Growing Adoption of Precision Medicine: Biomarker-driven treatment strategies are enabling personalized therapy selection and improving clinical outcomes.
• Emergence of Novel Oral SERDs: The approval and development of next-generation oral selective estrogen receptor degraders (SERDs) are expanding treatment options for ESR1-mutated disease.
• Robust Clinical Pipeline: Numerous investigational therapies, including SERDs, selective estrogen receptor covalent antagonists (SERCAs), PROTAC degraders, and combination regimens, are advancing through clinical trials.

ESR1 Mutated Metastatic Breast Cancer Market Barriers
• Development of Treatment Resistance: Tumors may develop additional resistance mechanisms even after treatment with next-generation endocrine therapies.
• High Cost of Targeted Therapies: Premium-priced novel endocrine agents and combination regimens may limit patient access and reimbursement.
• Limited Patient Population: ESR1 mutations occur in a subset of hormone receptor-positive metastatic breast cancer patients, restricting the addressable market.
• Need for Specialized Molecular Testing: Routine identification of ESR1 mutations depends on access to advanced genomic testing and liquid biopsy technologies.
• Variability in Testing Adoption: Limited availability and inconsistent use of biomarker testing across healthcare systems can delay appropriate treatment selection.

Scope of the ESR1 Mutated Metastatic Breast Cancer Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key ESR1 Mutated Metastatic Breast Cancer Companies: AstraZeneca, Sermonix Pharmaceuticals, Sun Pharma Advanced Research Company, Radius Pharmaceuticals/ Menarini Group, Pfizer, G1 Therapeutics, Sanofi, Sun PharmaAdvanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine/ Eisai, Roche, and others
• Key ESR1 Mutated Metastatic Breast Cancer Therapies: Camizestrant (AZD9833), Lasofoxifene, SCO-120, Elacestrant (RAD1901), Ibrance (Palbociclib), Amcenestrant, Rintodestrant (G1T48), G1 Therapeutics, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant(RG6171, GDC9545), and others
• ESR1 Mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1 Mutated Metastatic Breast Cancer current marketed and ESR1 Mutated Metastatic Breast Cancer emerging therapies
• ESR1 Mutated Metastatic Breast Cancer Market Dynamics: ESR1 Mutated Metastatic Breast Cancer market drivers and ESR1 Mutated Metastatic Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• ESR1 Mutated Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, ESR1 Mutated Metastatic Breast Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.